Diagnostyka S.a. · GPW:DIA
Diagnostyka — FY2024 Earnings Presentation
20 slides from Diagnostyka's earnings presentation, Apr 25, 2025
Slide 1: Financial results of the Diagnostyka Group for 2024
Financial results of the Diagnostyka Group for 2024 25 April 2025
Slide 2: Presenters
Presenters: Jakub Swadźba Paweł Chytła President of the Management Board, Vice President of the Management Board, Chief Executive Officer (CEO) Chief Financial Officer (CFO)
Slide 3: 2024 operational highlights
2024 operational highlights
Slide 4: 2024 summary
2024 summary Diagnostic tests over 25 million volume patients 1 161.3 million (CAGR 2011–2024: ca. 12%) Net profit attributable The Group’s revenue Recurring EBITDA2 to owners of the Parent PLN 1.97 PLN 223.3 PLN 508.7 billion million million (up 23.6% y/y) (up 32.8% y/y) (up 80.9% y/y) 1 Number of
Slide 5: Investments in laboratories, tests, IT and consolidation in 2024
We are investing in laboratories Opening of a new regional Full-scale launch of Expansion of the capacity laboratory in Łódź a new Abbott line of cytology laboratories and the largest anatomical pathology laboratory Preparations for launching the cervical cancer at the central laboratory in Kraków i
Slide 6: Strong investor interest and successful share flotation on the WSE
Strong investor interest and successful share flotation on the WSE + Sale of all Company shares held by MidEuropa Partners + PLN 105.00 – issue price of the shares + At the close of trading on the listing date, the Company's stock was valued at PLN 130.02, an increase of ca. 24% on the issue price (
Slide 7: Financial results
Financial results
Slide 8: Consistent growth of the business scale
/3 Consistent growth of the business scale PLN 1,950 million in 2024 23.1 % 1 y/y + 1,950 Revenue from contracts with customers (PLN million) 1,843 1,588 1,585 1,436 CAGR 2011–2024: 1,284 ca. 24% 1,138 1,127 806 779 694 580 494 421 361 311 263 123 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 20
Slide 9: Growth in revenue from contracts with customers
Growth in revenue from contracts with customers Revenue from contracts with customers (PLN million) Year-on-year 36.3% 13.9% 23.5% 23.1% growth1 (%): Excluding 1 COVID-19-related 1,950 + Revenue from contracts with customers, revenue. 1,843 1,588 excluding COVID-19-related revenue, rose by 23.1%. 1,
Slide 10: Operating expenses growing at a slower rate compared with revenue
Operating expenses growing at a slower rate compared with revenue Operating expenses (PLN million) Increase in operating 31.3% 3.6% 12.8% 20.1% + Operating expenses grew at a lower rate (+20.1% y/y) expenses (%): compared with revenue from contracts with customers Increase in revenue from contracts
Slide 11: Recurring EBITDA at PLN 508.7 million, up 32.8% y/y
Recurring EBITDA at PLN 508.7million, up 32.8% y/y Recurring EBITDA (PLN million) Recurring EBITDA 43.8% 26.0% 24.1% 26.1% margin (%): 807.9 + Recurring EBITDA margin improved by 2.0pp y/y, to 26.1%. 508.7 + The key growth driver was operating leverage. 373.1 383.0 2021 2022 2023 2024 Recurring EBIT
Slide 12: Consolidated statement of profit or loss of the Diagnostyka Group
Consolidated statement of profit or loss of the Diagnostyka Group The Group’s 2024 financial results by quarter (PLN million) Revenue from contracts with customers (PLN million) Q1 2024 Q2 2024 Q3 2024 Q4 2024 2024 483.6 505.3 480.5 480.8 Revenue 485.5 485.7 488.6 514.9 1,974.7 Revenue from contract
Slide 13: Significant increase in net profit year-on-year
Significant increase in net profit year-on-year Net profit 2023-2024 (PLN million) 125,6 7,3 -7,6 4,9 1,6 223,3 -14,3 -2,1 -15,6 123,4 Net profit attributable Recurring On-off items D&A Financial Income tax No impairment Share of profit or loss Net profit attributable Net profit attributable to owne
Slide 14: Robust cash flow supporting the Group's further growth and dividend distributions
Robust cash flow supporting the Group's further growth and dividend distributions Free cash flow (PLN million) + The largest component of the 2024 capex was FCF /EBITDA: 1 91.5% 76.4% 88.5% 85.3% expenditure on the construction of a laboratory in Łódź and 733.7 on the start of construction of a labo
Slide 15: Continued consolidation of the laboratory and imaging diagnostics market in 2024
Continued consolidation of the laboratory and imaging diagnostics market in 2024 Laboratory diagnostics services Medical imaging services PLN 15 million1 PLN 39.5 million1 M&A capex; 6 transactions M&A capex on new acquisitions; 3 transactions PLN 44.6 million M&A capex on the acquisition of control
Slide 16: Strong cash flow generation
Strong cash flow generation 2023 2024 Change Cash 2023–2024 (PLN million) y/y (PLN (PLN (PLN 499.5 (%)1 (%)1 million) million) million) Revenue 1,597.0 100.0% 1,974.7 100.0% 377.7 426.3 -55.6 -17.7 EBITDA2 381.5 23.9% 499.5 25.3% 118.0 Tax paid -36.7 -2.3% -55.6 -2.8% -18.8 Change in NWC3 -7.1 -0.4%
Slide 17: Stable net debt/EBITDA in 2023–2024
Stable net debt/EBITDA in 2023–2024 + Approximately 60% of the Group’s debt is financial debt (bank borrowings). + In Q4 2024, the Company increased its equity interests in Diagnostyka Wyrobek and Livmed (the transactions were financed with debt). + Given the Group’s increased M&A activity in the me
Slide 18: The Group's growth prospects in 2025
The Group's growth prospects in 2025 + Strong price increase in Q1 2025, complemented by stable volume growth. + Q1 2025 budget performance in line with the Group's expectations. + Further acquisitions in the medical imaging services segment. + As the Group continues acquisitions in the medical imag
Slide 19: Q&A
Q&A
Slide 20: Contact
Contact Michał Błasiński Investor Relations Director michal.blasinski@diag.pl Disclaimer This presentation has been prepared by Diagnostyka S.A. (the “Company”) for its shareholders, analysts, and other stakeholders. It is intended for informational purposes only and does not constitute an offer, or